<article article-type="other"> 
 <!--?properties open_acces=""?--> 
 <!-- Original-type: gg--> 
 <front> 
  <journal-meta> 
   <journal-id journal-id-type="nlm-ta">
     Br J Cancer 
   </journal-id> 
   <journal-h3>
     British Journal of Cancer 
   </journal-h3> 
   <issn pub-type="ppub">
     0007-0920 
   </issn> 
   <issn pub-type="epub">
     1532-1827 
   </issn> 
   <publisher> 
    <publisher-name>
      Nature Publishing Group 
    </publisher-name> 
   </publisher> 
  </journal-meta> 
  <article-meta> 
   <article-id pub-id-type="pmid">
     16175182 
   </article-id> 
   <article-id pub-id-type="pmc">
     2361658 
   </article-id> 
   <article-id pub-id-type="pii">
     6602790 
   </article-id> 
   <article-id pub-id-type="doi">
     10.1038/sj.bjc.6602790 
   </article-id> 
   <article-categories> 
    <subj-group subj-group-type="heading"> 
     <subject>
       Genetics and Genomics 
     </subject> 
    </subj-group> 
   </article-categories> 
   <h3-group> 
    <article-h3>
      Interaction between the bone morphogenetic proteins and Ras/MAP-kinase signalling pathways in lung cancer 
    </article-h3> 
   </h3-group> 
   <contrib-group> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Kraunz 
      </surname> 
      <given-names>
        K S 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff1">
       1 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Nelson 
      </surname> 
      <given-names>
        H H 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff2">
       2 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Liu 
      </surname> 
      <given-names>
        M 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff1">
       1 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Wiencke 
      </surname> 
      <given-names>
        J K 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff3">
       3 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Kelsey 
      </surname> 
      <given-names>
        K T 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff1">
       1 
     </xref> 
     <xref ref-type="corresp" rid="caf1">
       * 
     </xref> 
    </contrib> 
   </contrib-group> 
   <aff id="aff1"> 
    <label>1</label>Department of Genetics and Complex Diseases, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115, USA 
   </aff> 
   <aff id="aff2"> 
    <label>2</label>Department of Environmental Health, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115, USA 
   </aff> 
   <aff id="aff3"> 
    <label>3</label>Department of Neurological Surgery, Laboratory for Molecular Epidemiology, University of California at San Francisco, San Francisco, CA 94143-0441, USA 
   </aff> 
   <author-notes> 
    <corresp id="caf1"> 
     <label>*</label>Author for correspondence: 
     <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:kelsey@hsph.harvard.edu">
       kelsey@hsph.harvard.edu 
     </email> 
    </corresp> 
   </author-notes> 
   <pub-date pub-type="epub"> 
    <day>
      20 
    </day> 
    <month>
      09 
    </month> 
    <year>
      2005 
    </year> 
   </pub-date> 
   <pub-date pub-type="collection"> 
    <day>
      11 
    </day> 
    <month>
      10 
    </month> 
    <year>
      2005 
    </year> 
   </pub-date> 
   <pub-date pub-type="ppub"> 
    <day>
      17 
    </day> 
    <month>
      10 
    </month> 
    <year>
      2005 
    </year> 
   </pub-date> 
   <volume>
     93 
   </volume> 
   <issue>
     8 
   </issue> 
   <fpage>
     949 
   </fpage> 
   <lpage>
     952 
   </lpage> 
   <history> 
    <date date-type="received"> 
     <day>
       27 
     </day> 
     <month>
       05 
     </month> 
     <year>
       2005 
     </year> 
    </date> 
    <date date-type="rev-recd"> 
     <day>
       25 
     </day> 
     <month>
       07 
     </month> 
     <year>
       2005 
     </year> 
    </date> 
    <date date-type="accepted"> 
     <day>
       17 
     </day> 
     <month>
       08 
     </month> 
     <year>
       2005 
     </year> 
    </date> 
   </history> 
   <copyright-statement>
     Copyright 2005, Cancer Research UK 
   </copyright-statement> 
   <copyright-year>
     2005 
   </copyright-year> 
   <permissions> 
    <copyright-holder>
      Cancer Research UK 
    </copyright-holder> 
   </permissions> 
   <abstract> 
    <h3>Abstract</h3> 
    <p>Bone morphogenetic proteins (BMPs) are an integral component of the TGF 
     <italic>
       ? 
     </italic> superfamily, responsible for regulation of cell proliferation, differentiation, migration and programmed cell death in a variety of cell types. The BMPs transduce their signals directly through the SMAD family of proteins but they also have been reported to interact with the MAPK and Erk pathways. Inactivation of the BMP pathway genes has been implicated as important in several cancers. Recent work has shown that 
     <italic>
       BMP3b 
     </italic> is epigenetically inactivated in cancer and suggests that 
     <italic>
       BMP6 
     </italic> can be epigenetically inactivated. We investigated whether 
     <italic>
       BMP6 
     </italic> is epigenetically inactivated in cell lines and whether 
     <italic>
       BMP3b 
     </italic> and 
     <italic>
       BMP6 
     </italic> are epigenetically inactivated in non-small-cell lung cancer (NSCLC). We also studied the relationship between BMP methylation and 
     <italic>
       k-ras 
     </italic> mutation. Here, we demonstrate that the 
     <italic>
       BMP3b 
     </italic> and 
     <italic>
       BMP6 
     </italic> genes are common targets of epigenetic inactivation in NSCLC, and that they are significantly more likely to be concurrently inactivated ( 
     <italic>
       P 
     </italic>=0.009). Furthermore, this coinactivation of 
     <italic>
       BMP3b 
     </italic> and 
     <italic>
       BMP6 
     </italic> is significantly associated with mutation of 
     <italic>
       k-ras 
     </italic> codon 12 in lung cancer ( 
     <italic>
       P 
     </italic>=0.003); those with a 
     <italic>
       k-ras 
     </italic> mutation were six times more likely to have concurrent methylation of these BMP loci. Hence, these data suggest that concurrent inactivation of the BMP and activation of the Ras signalling pathways are important in lung carcinogenesis.</p> 
   </abstract> 
   <kwd-group> 
    <kwd>
      bone morphogenetic proteins 
    </kwd> 
    <kwd>
      methylation 
    </kwd> 
    <kwd>
      epigenetic inactivation 
    </kwd> 
    <kwd> 
     <italic>
       k-ras 
     </italic> mutation 
    </kwd> 
    <kwd>
      non-small-cell lung cancer 
    </kwd> 
   </kwd-group> 
  </article-meta> 
 </front> 
 <p> 
  <italic>
    k-ras 
  </italic> mutation, which leads to aberrant Ras/MAP-K pro-growth signalling, has been well studied in cancer ( 
  <xref ref-type="other" rid="bib4">
    Cunningham and Weinberg, 1985 
  </xref>; 
  <xref ref-type="other" rid="bib17">
    Nelson 
   <italic>
     et al 
   </italic>, 1999 
  </xref>; 
  <xref ref-type="other" rid="bib8">
    Huber and Stratakis, 2004 
  </xref>). However, additional signalling pathways are acknowledged to play important roles in malignant disease, with the bone morphogenetic protein (BMP) signalling pathway emerging as important in multiple cancers ( 
  <xref ref-type="other" rid="bib14">
    Nagatake 
   <italic>
     et al 
   </italic>, 1996 
  </xref>; 
  <xref ref-type="other" rid="bib20">
    Tamada 
   <italic>
     et al 
   </italic>, 2001 
  </xref>; 
  <xref ref-type="other" rid="bib2">
    Baldus 
   <italic>
     et al 
   </italic>, 2004 
  </xref>; 
  <xref ref-type="other" rid="bib5">
    Dai 
   <italic>
     et al 
   </italic>, 2004 
  </xref>; 
  <xref ref-type="other" rid="bib9">
    Kim 
   <italic>
     et al 
   </italic>, 2004 
  </xref>). It is well recognised that the BMP signalling pathways are crucial for all stages of embryonic development, including regulation of lung development and airway branching ( 
  <xref ref-type="other" rid="bib22">
    Weaver 
   <italic>
     et al 
   </italic>, 1999 
  </xref>; 
  <xref ref-type="other" rid="bib12">
    Lu 
   <italic>
     et al 
   </italic>, 2001 
  </xref>; 
  <xref ref-type="other" rid="bib18">
    Rosendahl 
   <italic>
     et al 
   </italic>, 2002 
  </xref>). The BMPs have been shown to be growth inhibitory by suppressing proliferation ( 
  <xref ref-type="other" rid="bib5">
    Dai 
   <italic>
     et al 
   </italic>, 2004 
  </xref>; 
  <xref ref-type="other" rid="bib7">
    Haudenschild 
   <italic>
     et al 
   </italic>, 2004 
  </xref>). They act through upregulation of the cell cycle proteins p21 and p27 ( 
  <xref ref-type="other" rid="bib15">
    Nakamura 
   <italic>
     et al 
   </italic>, 2003 
  </xref>; 
  <xref ref-type="other" rid="bib3">
    Brubaker 
   <italic>
     et al 
   </italic>, 2004 
  </xref>; 
  <xref ref-type="other" rid="bib7">
    Haudenschild 
   <italic>
     et al 
   </italic>, 2004 
  </xref>). The relationship between the TGF 
  <italic>
    ? 
  </italic>/BMP antigrowth and Ras/MAP-K progrowth signalling pathways remains unclear, but there is recent evidence of crosstalk between them ( 
  <xref ref-type="other" rid="bib10">
    Kretzschmar 
   <italic>
     et al 
   </italic>, 1997 
  </xref>; 
  <xref ref-type="other" rid="bib24">
    Yue 
   <italic>
     et al 
   </italic>, 1999 
  </xref>; 
  <xref ref-type="other" rid="bib21">
    Wach 
   <italic>
     et al 
   </italic>, 2001 
  </xref>). While BMP-2 stimulation of osteoblasts leads to activation of Ras ( 
  <xref ref-type="other" rid="bib16">
    Nakayama 
   <italic>
     et al 
   </italic>, 2003 
  </xref>), in 
  <italic>
    Xenopus 
  </italic>, BMP-4-stimulated erythroid differentiation is inhibited by dominant-negative activation of the Ras pathway ( 
  <xref ref-type="other" rid="bib23">
    Xu 
   <italic>
     et al 
   </italic>, 1996 
  </xref>). SMAD7, one of the inhibitory SMADs of the BMP/TGF 
  <italic>
    ? 
  </italic> signalling pathway, has been shown to cooperate with oncogenic Ras to escape growth arrest ( 
  <xref ref-type="other" rid="bib11">
    Liu 
   <italic>
     et al 
   </italic>, 2003 
  </xref>). While there is experimental evidence of an association between the BMP signalling proteins and oncogenic Ras, the nature of any interaction of BMP cytokine inactivation and 
  <italic>
    k-ras 
  </italic> mutation has been relatively unexplored in human tumours. As a result of the known importance of BMP signalling in the respiratory tract and the 
  <italic>
    in vitro 
  </italic> evidence of crosstalk between signalling pathways, we hypothesised that concurrent BMP inactivation and oncogenic 
  <italic>
    k-ras 
  </italic> mutation would be important in non-small-cell lung cancer (NSCLC).</p> 
 <sec sec-type="materials|methods"> 
  <h3>MATERIALS AND METHODS</h3> 
  <sec> 
   <h3>Study population</h3> 
   <p><span style="background-color:#ffffff">Eligible cases consisted of all the newly diagnosed patients with resectable lung cancer who received treatment at the Massachusetts General Hospital Thoracic Surgery Service from November 1992 to December 1996 ( Nelson et al , 1999 )</span>. <span style="background-color:#fffefe">All patients involved provided written informed consent in accordance with the appropriate institutional review boards</span>. <span style="background-color:#ffffff">Patients with recurrent disease or nonoperable tumours were excluded</span>. <span style="background-color:#fffdfd">Tumours were snap-frozen in liquid nitrogen and stored at ?80?C until genomic preparation</span>. <span style="background-color:#fff0f0">There were 155 cases with fresh tumour DNA available to be tested for BMP3b and BMP6 methylation</span>. <span style="background-color:#fff8f8">Demographic and epidemiologic data, including all of the data on tobacco use and occupational asbestos exposure, were obtained from a self-administered questionnaire completed by patients and subsequently reviewed by a single reviewer during the hospitalisation for thoracic surgery</span>. <span style="background-color:#ffffff">Asbestos exposure was defined as having any occupational asbestos exposure (yes/no), assessed as previously described ( Nelson et al , 1999 )</span></p> 
  </sec> 
  <sec> 
   <h3>Cell culture</h3> 
   <p><span style="background-color:#fffdfd">Lymphoblastic WTK1 and HT cells, small-cell carcinoma Shp77 cells, and non-small-cell carcinoma H322M and A549 cells were maintained in RPMI-1640 medium supplemented with 10% fetal calf serum</span>. <span style="background-color:#fffdfd">Prostate carcinoma DU145 cells and lung fibroblast IMR90 cells were maintained in minimum essential media (Eagle's) supplemented with 10% fetal calf serum</span>. <span style="background-color:#fffdfd">WTK1 cells (2 ? 105) in 10?ml media were treated with 1? ? l 5-aza-deoxycytadine in PBS or PBS alone for 3 days and then harvested</span></p> 
  </sec> 
  <sec> 
   <h3>Reverse transcription PCR</h3> 
   <p><span style="background-color:#ffffff">Total RNA was isolated using Qiagen RNeasy kit</span>. <span style="background-color:#ffffff">cDNA was synthesised from the RNA using the SuperScript III kit from Invitrogen</span>. <span style="background-color:#fffafa">Reverse transcription PCR (RT?PCR) amplification of the BMP6 cDNA was performed using primers designed with Primer3</span>. <span style="background-color:#fff9f9">The BMP6 primers used are as follows: 5?-ACA GCA TAA CAT GGG GCT TC-3? (sense) and 5?-CTC GGG GTT CAT AAG GTG AA-3?</span>. <span style="background-color:#ffffff">B-actin cDNA was amplified using primers supplied with the SuperScript III kit</span>. <span style="background-color:#ffffff">Approximately 50?ng of DNA was used as template</span>. The PCR mixture contained 10 ? PCR buffer, dNTPs (200? 
    <italic>
      ? 
    </italic> 
    <sc>
      M 
    </sc> of each), primers (1? 
    <italic>
      ? 
    </italic> 
    <sc>
      M 
    </sc> of each) and 0.25? 
    <italic>
      ? 
    </italic>l TaqGold. cDNA was amplified using an annealing temperature of 60?C over 35 cycles. <span style="background-color:#ffffff">PCR product was visualised on an ethidium bromide-stained agarose gel</span>.</p> 
  </sec> 
  <sec> 
   <h3>Methylation-specific PCR</h3> 
   <p><span style="background-color:#ffe4e4">Two sets of primers specific to the BMP6 promoter region were designed using Primer3 to amplify bisulphite-modified DNA; one specific for DNA methylated (M) at the promoter region and the other specific for unmethylated (U) DNA</span>. <span style="background-color:#fffefe">The primers used are as follows: (M) 5?-GGT TTG TTG GGT AGT CGG G-3? (sense) and GCC CCT CCC CAA ATC G-3? (antisense) and (U) 5?-TTG GGT AGT TGG GTG ATT GTT-3? (sense) and 5?-ACA CCC CTC CCC AAA TCA-3? (antisense)</span>. <span style="background-color:#ffffff">Approximately 50?ng of sodium bisuphfite-modified DNA was used as template</span>. <span style="background-color:#ffe5e5">The PCR mixture contained 10 ? PCR buffer, dNTPs (200? ? M of each), primers (1? ? M of each) and 0.25? ? l TaqGold</span>. <span style="background-color:#ffffff">Product was amplified using an annealing temperature of 60?C over 38 cycles</span>. <span style="background-color:#fffefe">Nontreated and Sss I methylase-treated lymphocytes were used as controls</span>. <span style="background-color:#fffefe">PCR products were separated by electrophoresis and visualised by ethidium bromide staining</span>.</p> 
  </sec> 
  <sec> 
   <h3>Statistical analysis</h3> 
   <p><span style="background-color:#ffffff">SAS software was used for statistical analysis</span>. <span style="background-color:#fffdfd">Wilcoxon rank sum test and Fisher's exact test (or ? 2 test) were used for continuous and categorical variables in univariate analysis, respectively</span>. <span style="background-color:#ffe5e5">Multivariate logistic regression was conducted to estimate the relationship between methylation of BMPs, k-ras mutation and covariates that were statistically significant in univariate analysis and that were important biologically</span>.</p> 
  </sec> 
 </sec> 
 <sec> 
  <h3>RESULTS</h3> 
  <sec> 
   <h3>Methylation of 
    <italic>
      BMP6 
    </italic> in cell lines</h3> 
   <p><span style="background-color:#fff1f1">In an effort to determine whether transcription of the BMP6 gene is inhibited by promoter methylation, we first examined the transcriptional status of BMP6 in cell lines using RT?PCR ( Figure 1A )</span>. <span style="background-color:#fff9f9">BMP6 mRNA was absent in WTK1 normal human lymphoblastoid cells</span>. <span style="background-color:#fff4f4">Following treatment with 5-aza-deoxycytadine, a DNA methyltransferase inhibitor, transcription was reactivated, demonstrating that the loss of transcription of BMP6 is due to epigenetic inactivation ( Figure 1B )</span>. <span style="background-color:#ffe4e4">Using primers designed specifically to differentiate between methylated and nonmethylated DNA at the BMP6 gene promoter, we demonstrated that the WTK1 cells are methylated at the BMP6 gene promoter ( Figure 1C )</span></p> 
  </sec> 
  <sec> 
   <h3>Methylation of 
    <italic>
      BMP3b 
    </italic> and 
    <italic>
      BMP6 
    </italic> in NSCLC cases</h3> 
   <p><span style="background-color:#ffd4d4">We evaluated BMP3b and BMP6 gene promoter methylation status in 155 NSCLC cases</span>. <span style="background-color:#ffd3d3">In a consecutive case series, we found that 57% (88 out of 155) and 43% (67 out of 155) of NSCLCs were methylated at the BMP3b and BMP6 gene promoters, respectively</span>. <span style="background-color:#ffe7e7">Since both BMP3b and BMP6 signal in the same pathways, we tested whether there was a relationship between inactivation of the two genes</span>. <span style="background-color:#ffe9e9">We found that 52% (46/88) of the cases with BMP3b methylation were also positive for BMP6 methylation; 31% (21/67) of cases without BMP3b methylation were positive for BMP6 methylation</span>. <span style="background-color:#ffbcbc">This statistically significant association between concurrent methylation of BMP3b and BMP6 ( P =0.009) indicates that the epigenetic silencing of these genes does not occur independently in lung cancer</span></p> 
  </sec> 
  <sec> 
   <h3>Relationship between BMP methylation and 
    <italic>
      k-ras 
    </italic> mutation in NSCLC</h3> 
   <p><span style="background-color:#ffeded">We next investigated the relationship between BMP epigenetic inactivation and k-ras mutation</span>. <span style="background-color:#fff0f0">We previously have reported the k-ras mutation status of these cases ( Nelson et al , 1999 )</span>. <span style="background-color:#ff5a5a">In the subset of cases with both k-ras and BMP data, 16% (24/147) were mutated at codon 12 of the k-ras gene and BMP3b methylation was significantly associated with k-ras mutation ( Table 1 , P &lt;0.03)</span>. <span style="background-color:#ffe3e3">Those with BMP6 methylation were more likely to have k-ras mutation, but this was not statistically significant</span>. <span style="background-color:#ff8585">However, concurrent methylation of both BMP3b and BMP6 was strongly associated with k-ras mutation ( Table 1 , P &lt;0.003)</span></p> 
  </sec> 
  <sec> 
   <h3>Concurrent BMP methylation, 
    <italic>
      k-ras 
    </italic> mutation, and tobacco and asbestos exposure in NSCLC</h3> 
   <p><span style="background-color:#ffeeee">k-ras mutation has previously been associated with asbestos exposure in these patients ( Nelson et al , 1999 )</span>. <span style="background-color:#fffefe">In addition, pulmonary interstitial fibrosis (a condition associated with asbestos exposure) is associated with activation of the BMP/SMAD signalling pathway ( Matsuse et al , 1996 ; Rosendahl et al , 2002 )</span>. <span style="background-color:#ffdfdf">Therefore, we examined the relationship between tobacco use, asbestos exposure and k-ras mutation, and epigenetic silencing of the BMPs ( Table 2 )</span>. <span style="background-color:#ffbcbc">A logistic regression analysis, controlling for histology and gender showed that tumours with k-ras mutation are six-fold more likely to have concurrent BMP3/6 silencing (OR=6.0, 95% confidence interval (CI) =2.0?17.9) and asbestos exposure significantly decreased the likelihood of concurrent BMP3/6 methylation (OR=0.2, CI 0.1?0.9; Table 2 )</span>. <span style="background-color:#ffdddd">There was no statistically significant relationship between BMP methylation and tobacco exposure ( Table 2 )</span></p> 
  </sec> 
 </sec> 
 <sec> 
  <h3>DISCUSSION</h3> 
  <p><span style="background-color:#fffefe">The BMPs are well recognised to play multiple crucial roles in the development of diverse tissues</span>. <span style="background-color:#fff7f7">They are also believed to play a role in the genesis of many tumour types, with their inactivation allowing for dysregulated cellular proliferation</span>. <span style="background-color:#ffffff">There are multiple BMPs with overlapping substrate specificity ( Stott et al , 1998 )</span>. <span style="background-color:#ffd6d6">Our data, showing that epigenetic inactivation of BMP3b (at a frequency similar to that previously reported ( Dai et al , 2004 )) and BMP6 tend to occur together in lung cancer, suggests that in NSCLC multiple BMPs may need to be silenced in order to abrogate their antigrowth signalling</span></p> 
  <p><span style="background-color:#fff8f8">Increasing evidence shows that there is a crosstalk between TGF ? /BMP antigrowth signalling and Ras/MAP-K progrowth signalling, and it is likely that the interaction of these pathways is cell type and tissue specific</span>. <span style="background-color:#ffffff">Some evidence suggests that Ras inactivates SMAD signalling while other evidence suggests that Ras activates SMAD signalling ( Kretzschmar et al , 1997 ; Yue et al , 1999 )</span>. <span style="background-color:#ffeeee">Further, inhibitory SMADs have been shown to be upregulated in coordination with k-ras mutation in epithelial cancer ( Liu et al , 2003 )</span>. <span style="background-color:#fffdfd">Although the exact relationship between BMPs and Ras in signalling are unclear, our data are consistent with the mounting evidence that the relationship is important in solid tumours</span>.</p> 
  <p><span style="background-color:#ffe6e6">The finding that asbestos exposure is associated with a significantly different pattern of signalling dysregulation in NSCLC supports the notion that clonal selection has important nodal points that are influenced by the pattern of carcinogen exposure</span>. <span style="background-color:#ffeded">The current work suggests that the Ras and BMP pathways are part of a complex network of inter-related and interacting signalling proteins where multiple factors, including carcinogen exposure, determine the precise character of somatic genes inactivated in this particular tumour, NSCLC</span>. <span style="background-color:#ffecec">In the case of BMP inactivation, there was no apparent association of methylation silencing with tobacco exposure</span>. <span style="background-color:#fff5f5">However, we identified an inverse relationship between asbestos exposure and BMP methylation</span>. <span style="background-color:#fffefe">Asbestos exposure has been associated with cytogenetic damage in humans ( Dusinska et al , 2004 )</span>. <span style="background-color:#ffffff">Hence, asbestos may be selecting for pathway inactivation via large-scale genetic changes</span>. <span style="background-color:#ffdada">For example, SMAD4, the effector protein in the BMP pathway, has been identified as mutated and deleted in lung cancer ( Nagatake et al , 1996 ; An et al , 2002 )</span>. <span style="background-color:#fff4f4">If asbestos were associated with induction of SMAD4 inactivation in lung cancer, one would expect the inverse association with BMP silencing that we have observed</span>.</p> 
  <p><span style="background-color:#fffefe">The balance between antigrowth and progrowth signalling that is imperative for normal cell development and homeostasis is reliant upon multiple feedback signalling pathways</span>. <span style="background-color:#ffe7e7">k-ras mutation has been described as a relatively early event in cancer ( Nelson et al , 1999 ) that constitutively activates the protein leading to active growth signalling</span>. <span style="background-color:#ffd5d5">Our data show that the BMP pathway, which is antiproliferative, is selected for inactivation preferentially in k-ras mutant tumours in NSCLC, likely as a direct means of potentiating progrowth signalling</span>. <span style="background-color:#fff6f6">Direct experimental investigation of this interaction in human cells and a description of the effects of different carcinogens in different tissues upon the disruption of this signalling are clearly indicated</span>. <span style="background-color:#fffdfd">This will more precisely define the aetiologic effects of carcinogens (such as asbestos), delineate the interlocking pathways that are dysregulated in solid tumours, and potentially open avenues for prevention and treatment of these often-fatal cancers.</span></p> 
 </sec> 
 <back> 
  <ack> 
   <p>This work was supported by CA100679, CA078609 and ES00002.</p> 
  </ack> 
  <ref-list> 
   <ref id="bib1"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         An 
       </surname> 
       <given-names>
         Q 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Liu 
       </surname> 
       <given-names>
         Y 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gao 
       </surname> 
       <given-names>
         Y 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Huang 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Fong 
       </surname> 
       <given-names>
         X 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Liu 
       </surname> 
       <given-names>
         L 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Zhang 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Zhang 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Cheng 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Deletion of tumor suppressor genes in Chinese non-small cell lung cancer 
     </article-h3> 
     <source />Cancer Lett 
     <year>
       2002 
     </year> 
     <volume>
       184 
     </volume> 
     <fpage>
       189 
     </fpage> 
     <lpage>
       195 
     </lpage> 
     <!--PubMed citation query: 'Cancer Lett||184|189||bib1|'--> 
     <pub-id pub-id-type="pmid">
       12127691 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib2"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Baldus 
       </surname> 
       <given-names>
         SE 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Schwarz 
       </surname> 
       <given-names>
         E 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lohrey 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Zapatka 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Landsberg 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hahn 
       </surname> 
       <given-names>
         SA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Schmidt 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Dienes 
       </surname> 
       <given-names>
         HP 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Schmiegel 
       </surname> 
       <given-names>
         WH 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Schwarte-Waldhoff 
       </surname> 
       <given-names>
         I 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Smad4 deficiency in cervical carcinoma cells 
     </article-h3> 
     <source />Oncogene 
     <year>
       2004 
     </year> 
     <volume>
       24 
     </volume> 
     <fpage>
       810 
     </fpage> 
     <lpage>
       819 
     </lpage> 
     <!--PubMed citation query: 'Oncogene||24|810||bib2|'--> 
     <pub-id pub-id-type="pmid">
       15531914 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib3"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Brubaker 
       </surname> 
       <given-names>
         KD 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Corey 
       </surname> 
       <given-names>
         E 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Brown 
       </surname> 
       <given-names>
         LG 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Vessella 
       </surname> 
       <given-names>
         RL 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Bone morphogenetic protein signaling in prostate cancer cell lines 
     </article-h3> 
     <source />J Cell Biochem 
     <year>
       2004 
     </year> 
     <volume>
       91 
     </volume> 
     <fpage>
       151 
     </fpage> 
     <lpage>
       160 
     </lpage> 
     <!--PubMed citation query: 'J Cell Biochem||91|151||bib3|'--> 
     <pub-id pub-id-type="pmid">
       14689587 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib4"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Cunningham 
       </surname> 
       <given-names>
         JM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Weinberg 
       </surname> 
       <given-names>
         RA 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Ras oncogenes in human tumours: identification, mechanism of activation and cooperative role in transformation 
     </article-h3> 
     <source />IARC Sci Publ 
     <year>
       1985 
     </year> 
     <volume>
       60 
     </volume> 
     <fpage>
       359 
     </fpage> 
     <lpage>
       364 
     </lpage> 
     <!--PubMed citation query: 'IARC Sci Publ||60|359||bib4|'--> 
     <pub-id pub-id-type="pmid">
       4065948 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib5"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Dai 
       </surname> 
       <given-names>
         Z 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Popkie 
       </surname> 
       <given-names>
         AP 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Zhu 
       </surname> 
       <given-names>
         WG 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Timmers 
       </surname> 
       <given-names>
         CD 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Raval 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tannehill-Gregg 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Morrison 
       </surname> 
       <given-names>
         CD 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Auer 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kratzke 
       </surname> 
       <given-names>
         RA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Niehans 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Amatschek 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sommergruber 
       </surname> 
       <given-names>
         W 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Leone 
       </surname> 
       <given-names>
         GW 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Rosol 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Otterson 
       </surname> 
       <given-names>
         GA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Plass 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Bone morphogenetic protein 3B silencing in non-small-cell lung cancer 
     </article-h3> 
     <source />Oncogene 
     <year>
       2004 
     </year> 
     <volume>
       23 
     </volume> 
     <fpage>
       3521 
     </fpage> 
     <lpage>
       3529 
     </lpage> 
     <!--PubMed citation query: 'Oncogene||23|3521||bib5|'--> 
     <pub-id pub-id-type="pmid">
       15116090 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib6"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Dusinska 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Collins 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kazimirova 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Barancokova 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Harrington 
       </surname> 
       <given-names>
         V 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Volkovova 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Staruchova 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Horska 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Wsolova 
       </surname> 
       <given-names>
         L 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kocan 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Petrik 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Machata 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ratcliffe 
       </surname> 
       <given-names>
         B 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kyrtopoulos 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Genotoxic effects of asbestos in humans 
     </article-h3> 
     <source />Mutat Res 
     <year>
       2004 
     </year> 
     <volume>
       553 
     </volume> 
     <fpage>
       91 
     </fpage> 
     <lpage>
       102 
     </lpage> 
     <!--PubMed citation query: 'Mutat Res||553|91||bib6|'--> 
     <pub-id pub-id-type="pmid">
       15288536 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib7"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Haudenschild 
       </surname> 
       <given-names>
         DR 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Palmer 
       </surname> 
       <given-names>
         SM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Moseley 
       </surname> 
       <given-names>
         TA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         You 
       </surname> 
       <given-names>
         Z 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Reddi 
       </surname> 
       <given-names>
         AH 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer 
     </article-h3> 
     <source />Cancer Res 
     <year>
       2004 
     </year> 
     <volume>
       64 
     </volume> 
     <fpage>
       8276 
     </fpage> 
     <lpage>
       8284 
     </lpage> 
     <!--PubMed citation query: 'Cancer Res||64|8276||bib7|'--> 
     <pub-id pub-id-type="pmid">
       15548695 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib8"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Huber 
       </surname> 
       <given-names>
         RM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Stratakis 
       </surname> 
       <given-names>
         DF 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Molecular oncology ? perspectives in lung cancer 
     </article-h3> 
     <source />Lung Cancer 
     <year>
       2004 
     </year> 
     <volume>
       45 
     </volume> 
     <supplement>
       Suppl 2 
     </supplement> 
     <fpage>
       S209 
     </fpage> 
     <lpage>
       S213 
     </lpage> 
     <!--PubMed citation query: 'Lung Cancer||45|S209||bib8|'--> 
     <pub-id pub-id-type="pmid">
       15552801 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib9"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Kim 
       </surname> 
       <given-names>
         IY 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lee 
       </surname> 
       <given-names>
         DH 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lee 
       </surname> 
       <given-names>
         DK 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ahn 
       </surname> 
       <given-names>
         HJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kim 
       </surname> 
       <given-names>
         MM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kim 
       </surname> 
       <given-names>
         SJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Morton 
       </surname> 
       <given-names>
         RA 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells 
     </article-h3> 
     <source />Oncogene 
     <year>
       2004 
     </year> 
     <volume>
       23 
     </volume> 
     <fpage>
       7651 
     </fpage> 
     <lpage>
       7659 
     </lpage> 
     <!--PubMed citation query: 'Oncogene||23|7651||bib9|'--> 
     <pub-id pub-id-type="pmid">
       15354178 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib10"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Kretzschmar 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Doody 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Massague 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1 
     </article-h3> 
     <source />Nature 
     <year>
       1997 
     </year> 
     <volume>
       389 
     </volume> 
     <fpage>
       618 
     </fpage> 
     <lpage>
       622 
     </lpage> 
     <!--PubMed citation query: 'Nature||389|618||bib10|'--> 
     <pub-id pub-id-type="pmid">
       9335504 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib11"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Liu 
       </surname> 
       <given-names>
         X 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lee 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Cooley 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bhogte 
       </surname> 
       <given-names>
         E 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hartley 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Glick 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Smad7 but not Smad6 cooperates with oncogenic ras to cause malignant conversion in a mouse model for squamous cell carcinoma 
     </article-h3> 
     <source />Cancer Res 
     <year>
       2003 
     </year> 
     <volume>
       63 
     </volume> 
     <fpage>
       7760 
     </fpage> 
     <lpage>
       7768 
     </lpage> 
     <!--PubMed citation query: 'Cancer Res||63|7760||bib11|'--> 
     <pub-id pub-id-type="pmid">
       14633701 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib12"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Lu 
       </surname> 
       <given-names>
         MM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Yang 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Zhang 
       </surname> 
       <given-names>
         L 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Shu 
       </surname> 
       <given-names>
         W 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Blair 
       </surname> 
       <given-names>
         DG 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Morrisey 
       </surname> 
       <given-names>
         EE 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       The bone morphogenic protein antagonist gremlin regulates proximal?distal patterning of the lung 
     </article-h3> 
     <source />Dev Dyn 
     <year>
       2001 
     </year> 
     <volume>
       222 
     </volume> 
     <fpage>
       667 
     </fpage> 
     <lpage>
       680 
     </lpage> 
     <!--PubMed citation query: 'Dev Dyn||222|667||bib12|'--> 
     <pub-id pub-id-type="pmid">
       11748835 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib13"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Matsuse 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ikegami 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ohga 
       </surname> 
       <given-names>
         E 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hosoi 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Oka 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kida 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Fukayama 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Inoue 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Nagase 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ouchi 
       </surname> 
       <given-names>
         Y 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Fukuchi 
       </surname> 
       <given-names>
         Y 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Expression of immunoreactive activin A protein in remodeling lesions associated with interstitial pulmonary fibrosis 
     </article-h3> 
     <source />Am J Pathol 
     <year>
       1996 
     </year> 
     <volume>
       148 
     </volume> 
     <fpage>
       707 
     </fpage> 
     <lpage>
       713 
     </lpage> 
     <!--PubMed citation query: 'Am J Pathol||148|707||bib13|'--> 
     <pub-id pub-id-type="pmid">
       8774126 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib14"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Nagatake 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Takagi 
       </surname> 
       <given-names>
         Y 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Osada 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Uchida 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Mitsudomi 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Saji 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Shimokata 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Takahashi 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Somatic 
      <italic>
        in vivo 
      </italic> alterations of the DPC4 gene at 18q21 in human lung cancers 
     </article-h3> 
     <source />Cancer Res 
     <year>
       1996 
     </year> 
     <volume>
       56 
     </volume> 
     <fpage>
       2718 
     </fpage> 
     <lpage>
       2720 
     </lpage> 
     <!--PubMed citation query: 'Cancer Res||56|2718||bib14|'--> 
     <pub-id pub-id-type="pmid">
       8665501 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib15"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Nakamura 
       </surname> 
       <given-names>
         Y 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ozaki 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Koseki 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Nakagawara 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sakiyama 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Accumulation of p27 KIP1 is associated with BMP2-induced growth arrest and neuronal differentiation of human neuroblastoma-derived cell lines 
     </article-h3> 
     <source />Biochem Biophys Res Commun 
     <year>
       2003 
     </year> 
     <volume>
       307 
     </volume> 
     <fpage>
       206 
     </fpage> 
     <lpage>
       213 
     </lpage> 
     <!--PubMed citation query: 'Biochem Biophys Res Commun||307|206||bib15|'--> 
     <pub-id pub-id-type="pmid">
       12850001 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib16"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Nakayama 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tamura 
       </surname> 
       <given-names>
         Y 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Suzawa 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Harada 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Fukumoto 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kato 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Miyazono 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Rodan 
       </surname> 
       <given-names>
         GA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Takeuchi 
       </surname> 
       <given-names>
         Y 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Fujita 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Receptor tyrosine kinases inhibit bone morphogenetic protein-Smad responsive promoter activity and differentiation of murine MC3T3-E1 osteoblast-like cells 
     </article-h3> 
     <source />J Bone Miner Res 
     <year>
       2003 
     </year> 
     <volume>
       18 
     </volume> 
     <fpage>
       827 
     </fpage> 
     <lpage>
       835 
     </lpage> 
     <!--PubMed citation query: 'J Bone Miner Res||18|827||bib16|'--> 
     <pub-id pub-id-type="pmid">
       12733721 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib17"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Nelson 
       </surname> 
       <given-names>
         HH 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Christiani 
       </surname> 
       <given-names>
         DC 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Wiencke 
       </surname> 
       <given-names>
         JK 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Mark 
       </surname> 
       <given-names>
         EJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Wain 
       </surname> 
       <given-names>
         JC 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kelsey 
       </surname> 
       <given-names>
         KT 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       k-ras mutation and occupational asbestos exposure in lung adenocarcinoma: asbestos-related cancer without asbestosis 
     </article-h3> 
     <source />Cancer Res 
     <year>
       1999 
     </year> 
     <volume>
       59 
     </volume> 
     <fpage>
       4570 
     </fpage> 
     <lpage>
       4573 
     </lpage> 
     <!--PubMed citation query: 'Cancer Res||59|4570||bib17|'--> 
     <pub-id pub-id-type="pmid">
       10493509 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib18"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Rosendahl 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Pardali 
       </surname> 
       <given-names>
         E 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Speletas 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ten Dijke 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Heldin 
       </surname> 
       <given-names>
         CH 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sideras 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Activation of bone morphogenetic protein/Smad signaling in bronchial epithelial cells during airway inflammation 
     </article-h3> 
     <source />Am J Respir Cell Mol Biol 
     <year>
       2002 
     </year> 
     <volume>
       27 
     </volume> 
     <fpage>
       160 
     </fpage> 
     <lpage>
       169 
     </lpage> 
     <!--PubMed citation query: 'Am J Respir Cell Mol Biol||27|160||bib18|'--> 
     <pub-id pub-id-type="pmid">
       12151307 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib19"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Stott 
       </surname> 
       <given-names>
         FJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bates 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         James 
       </surname> 
       <given-names>
         MC 
       </given-names> 
      </name> 
      <name> 
       <surname>
         McConnell 
       </surname> 
       <given-names>
         BB 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Starborg 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Brookes 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Palmero 
       </surname> 
       <given-names>
         I 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ryan 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hara 
       </surname> 
       <given-names>
         E 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Vousden 
       </surname> 
       <given-names>
         KH 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Peters 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2 
     </article-h3> 
     <source />EMBO J 
     <year>
       1998 
     </year> 
     <volume>
       17 
     </volume> 
     <fpage>
       5001 
     </fpage> 
     <lpage>
       5014 
     </lpage> 
     <!--PubMed citation query: 'EMBO J||17|5001||bib19|'--> 
     <pub-id pub-id-type="pmid">
       9724636 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib20"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Tamada 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kitazawa 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gohji 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kitazawa 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Epigenetic regulation of human bone morphogenetic protein 6 gene expression in prostate cancer 
     </article-h3> 
     <source />J Bone Miner Res 
     <year>
       2001 
     </year> 
     <volume>
       16 
     </volume> 
     <fpage>
       487 
     </fpage> 
     <lpage>
       496 
     </lpage> 
     <!--PubMed citation query: 'J Bone Miner Res||16|487||bib20|'--> 
     <pub-id pub-id-type="pmid">
       11277266 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib21"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Wach 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Schirmacher 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Protschka 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Blessing 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Overexpression of bone morphogenetic protein-6 (BMP-6) in murine epidermis suppresses skin tumor formation by induction of apoptosis and downregulation of fos/jun family members 
     </article-h3> 
     <source />Oncogene 
     <year>
       2001 
     </year> 
     <volume>
       20 
     </volume> 
     <fpage>
       7761 
     </fpage> 
     <lpage>
       7769 
     </lpage> 
     <!--PubMed citation query: 'Oncogene||20|7761||bib21|'--> 
     <pub-id pub-id-type="pmid">
       11753654 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib22"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Weaver 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Yingling 
       </surname> 
       <given-names>
         JM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Dunn 
       </surname> 
       <given-names>
         NR 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bellusci 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hogan 
       </surname> 
       <given-names>
         BL 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Bmp signaling regulates proximal?distal differentiation of endoderm in mouse lung development 
     </article-h3> 
     <source />Development 
     <year>
       1999 
     </year> 
     <volume>
       126 
     </volume> 
     <fpage>
       4005 
     </fpage> 
     <lpage>
       4015 
     </lpage> 
     <!--PubMed citation query: 'Development||126|4005||bib22|'--> 
     <pub-id pub-id-type="pmid">
       10457010 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib23"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Xu 
       </surname> 
       <given-names>
         RH 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Dong 
       </surname> 
       <given-names>
         Z 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Maeno 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kim 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Suzuki 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ueno 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sredni 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Colburn 
       </surname> 
       <given-names>
         NH 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kung 
       </surname> 
       <given-names>
         HF 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Involvement of Ras/Raf/AP-1 in BMP-4 signaling during 
      <italic>
        Xenopus 
      </italic> embryonic development 
     </article-h3> 
     <source />Proc Natl Acad Sci USA 
     <year>
       1996 
     </year> 
     <volume>
       93 
     </volume> 
     <fpage>
       834 
     </fpage> 
     <lpage>
       838 
     </lpage> 
     <!--PubMed citation query: 'Proc Natl Acad Sci USA||93|834||bib23|'--> 
    </citation> 
   </ref> 
   <ref id="bib24"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Yue 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Frey 
       </surname> 
       <given-names>
         RS 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Mulder 
       </surname> 
       <given-names>
         KM 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Cross-talk between the Smad1 and Ras/MEK signaling pathways for TGFbeta 
     </article-h3> 
     <source />Oncogene 
     <year>
       1999 
     </year> 
     <volume>
       18 
     </volume> 
     <fpage>
       2033 
     </fpage> 
     <lpage>
       2037 
     </lpage> 
     <!--PubMed citation query: 'Oncogene||18|2033||bib24|'--> 
     <pub-id pub-id-type="pmid">
       10208426 
     </pub-id> 
    </citation> 
   </ref> 
  </ref-list> 
 </back> 
 <floats-wrap> 
  <fig id="fig1"> 
   <label>Figure 1</label> 
   <p>
    <italic>
      BMP6 
    </italic> is epigenetically inactivated in cancer cell lines. ( 
    <bold>
      A 
    </bold>) BMP6 <span style="background-color:#ffffff">cDNA was amplified using an annealing temperature of 60?C over 35 cycles</span> with the following primers: 5?-ACA GCA TAA CAT GGG GCT TC-3? (sense) and 5?-CTC GGG GTT CAT AAG GTG AA-3? (antisense). The WTK1 and HT cell lines did not express BMP6. ( 
    <bold>
      B 
    </bold>) WTK1 cells were treated with 1? 
    <italic>
      ? 
    </italic>l 5-aza-deoxycytadine in PBS or PBS alone for 3 days and then harvested. BMP6 is re-expressed in the WTK1 cells. ( 
    <bold>
      C 
    </bold>) The 
    <italic>
      BMP6 
    </italic> gene promoter methylation status was determined by amplifying bisulphite-modified DNA using primers specific to methylated (M) and unmethylated (U) DNA. The DNA was amplified using an annealing temperature of 60?C over 38 cycles with the following primers: (M) 5?-GGT TTG TTG GGT AGT CGG G-3? (sense) and GCC CCT CCC CAA ATC G-3? (antisense) and (U) 5?-TTG GGT AGT TGG GTG ATT GTT-3? (sense) and 5?-ACA CCC CTC CCC AAA TCA-3? (antisense).</p> 
   <graphic mime-subtype="jpeg" xlink:href="93-6602790f1"></graphic> 
  </fig> 
  <table-wrap id="tbl1" position="float"> 
   <label>Table 1</label> 
   <p content-type="table-h3">BMP methylation and 
    <italic>
      k-ras 
    </italic> mutation in NSCLC</p> 
   <table border="1" frame="hsides" rules="groups" width="85%"> 
    <colgroup> 
     <col align="left" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
    </colgroup> 
    <thead valign="bottom"> 
     <tr> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
      <th align="center" charoff="50" colspan="3" valign="top"> 
       <bold> 
        <italic>
          BMP3B 
        </italic> methylation 
       </bold> </th> 
      <th align="center" charoff="50" colspan="3" valign="top"> 
       <bold> 
        <italic>
          BMP6 
        </italic> methylation 
       </bold> </th> 
      <th align="center" charoff="50" colspan="3" valign="top"> 
       <bold>
         Concurrent 
        <italic>
          BMP3b 
        </italic> and 
        <italic>
          BMP6 
        </italic> methylation 
       </bold> </th> 
     </tr> 
     <tr> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         NM 
        <sup>a</sup> 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         M 
        <sup>a</sup> 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold> 
        <italic>
          P 
        </italic>-value 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         NM 
        <sup>a</sup> 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         M 
        <sup>a</sup> 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold> 
        <italic>
          P 
        </italic>-value 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         NM 
        <sup>a</sup> 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         M 
        <sup>a</sup> 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold> 
        <italic>
          P 
        </italic>-value 
       </bold> </th> 
     </tr> 
    </thead> 
    <tbody valign="top"> 
     <tr> 
      <td align="left" charoff="50" valign="top">Overall prevalence in NSCLC (n (%))</td> 
      <td align="center" charoff="50" valign="top">68 (44%)</td> 
      <td align="center" charoff="50" valign="top">88 (56%)</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">96 (60%)</td> 
      <td align="center" charoff="50" valign="top">63 (40%)</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" colspan="10" valign="top"> 
       <italic>
         k-ras mutation (codon 12) 
       </italic> </td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?Not mutated (%)</td> 
      <td align="center" charoff="50" valign="top">62 (91)</td> 
      <td align="center" charoff="50" valign="top">69 (78)</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">82 (87)</td> 
      <td align="center" charoff="50" valign="top">49 (78)</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">93 (89)</td> 
      <td align="center" charoff="50" valign="top">30 (70)</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?Mutated (%)</td> 
      <td align="center" charoff="50" valign="top">6 (9)</td> 
      <td align="center" charoff="50" valign="top">19 (22)</td> 
      <td align="center" charoff="50" valign="top">0.03<sup>b</sup></td> 
      <td align="center" charoff="50" valign="top">12 (13)</td> 
      <td align="center" charoff="50" valign="top">14 (22)</td> 
      <td align="center" charoff="50" valign="top">0.12<sup>b</sup></td> 
      <td align="center" charoff="50" valign="top">11 (11)</td> 
      <td align="center" charoff="50" valign="top">13 (30)</td> 
      <td align="center" charoff="50" valign="top">0.003<sup>b</sup></td> 
     </tr> 
    </tbody> 
   </table> 
   <table-wrap-foot> 
    <fn id="tbfnote1"> 
     <label>a</label> 
     <p>NM=not methylated; M=methylated.</p> 
    </fn> 
    <fn id="tbfnote2"> 
     <label>b</label> 
     <p>?<sup>2</sup> test.</p> 
    </fn> 
   </table-wrap-foot> 
  </table-wrap> 
  <table-wrap id="tbl2" position="float"> 
   <label>Table 2</label> 
   <p content-type="table-h3">Logistic regression modelling of BMP methylation and 
    <italic>
      k-ras 
    </italic> mutation in NSCLC</p> 
   <table border="1" frame="hsides" rules="groups" width="85%"> 
    <colgroup> 
     <col align="left" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
    </colgroup> 
    <thead valign="bottom"> 
     <tr> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
      <th align="center" charoff="50" colspan="2" valign="top"> 
       <bold> 
        <italic>
          BMP3b 
        </italic> Meth 
       </bold> </th> 
      <th align="center" charoff="50" colspan="2" valign="top"> 
       <bold> 
        <italic>
          BMP6 
        </italic> Meth 
       </bold> </th> 
      <th align="center" charoff="50" colspan="2" valign="top"> 
       <bold>
         Concurrent 
        <italic>
          BMP3b 
        </italic> and 
        <italic>
          BMP6 
        </italic> Meth 
       </bold> </th> 
     </tr> 
     <tr> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         OR 
        <sup>a</sup> 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         CI 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         OR 
        <sup>a</sup> 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         CI 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         OR 
        <sup>a</sup> 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         CI 
       </bold> </th> 
     </tr> 
    </thead> 
    <tbody valign="top"> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 
       <italic>
         k-ras 
       </italic> mutation</td> 
      <td align="center" charoff="50" valign="top">3.7</td> 
      <td align="center" charoff="50" valign="top">1.2, 11.4</td> 
      <td align="center" charoff="50" valign="top">2.9</td> 
      <td align="center" charoff="50" valign="top">1.1, 7.7</td> 
      <td align="center" charoff="50" valign="top">6.0</td> 
      <td align="center" charoff="50" valign="top">2.0, 17.9</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">Asbestos exposure</td> 
      <td align="center" charoff="50" valign="top">0.2</td> 
      <td align="center" charoff="50" valign="top">0.1, 0.6</td> 
      <td align="center" charoff="50" valign="top">0.3</td> 
      <td align="center" charoff="50" valign="top">0.1, 1.0</td> 
      <td align="center" charoff="50" valign="top">0.2</td> 
      <td align="center" charoff="50" valign="top">0.04, 0.9</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">Pack-years</td> 
      <td align="center" charoff="50" valign="top">1.002</td> 
      <td align="center" charoff="50" valign="top">0.992, 1.012</td> 
      <td align="center" charoff="50" valign="top">0.998</td> 
      <td align="center" charoff="50" valign="top">0.988, 1.008</td> 
      <td align="center" charoff="50" valign="top">1.003</td> 
      <td align="center" charoff="50" valign="top">0.922, 1.015</td> 
     </tr> 
    </tbody> 
   </table> 
   <table-wrap-foot> 
    <fn id="tbfnote3"> 
     <label>a</label> 
     <p>Controlling for gender and histology.</p> 
    </fn> 
   </table-wrap-foot> 
  </table-wrap> 
 </floats-wrap> 
</article>